Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Amicus Therapeutics Inc (NASDAQ:FOLD)

14.89
Delayed Data
As of Sep 03
 -0.02 / -0.13%
Today’s Change
5.13
Today|||52-Week Range
18.83
+78.97%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.8B

Company Description

Amicus Therapeutics, Inc. is a biopharmaceutical company focuses on the discovery, development and commercialization of orally administered, small molecule drugs known as pharmacological chaperones for the treatment of rare diseases, pharmacological chaperones are a novel, first-in-class approach to treating a broad range of diseases, including lysosomal storage disorders and diseases of neurodegeneration. Amicus develops pharmacological chaperones oral therapies that bind to and stabilize the affected proteins, restoring their shape, proper trafficking, and biological activity. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.

Contact Information

Amicus Therapeutics, Inc.
1 Cedar Brook Drive
Cranbury New Jersey 08512
P:(609) 662-2000
Investor Relations:
(609) 662-5044

Employees

Shareholders

Other institutional65.63%
Mutual fund holders39.92%
Individual stakeholders39.64%

Top Executives

John Francis CrowleyChairman & Chief Executive Officer
Bradley L. CampbellPresident & Chief Operating Officer
William D. BairdChief Financial Officer
Enrique DiloneVice President-Technical Operations
Robert E. WinklerVice President-Clinical Research & Operations